Sorafenib: A Review in Hepatocellular Carcinoma
1Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand. demail@springer.com.
Targeted Oncology
|March 17, 2017
Summary
Sorafenib is the sole approved systemic treatment for advanced hepatocellular carcinoma (HCC), demonstrating improved survival in clinical trials. Real-world data support its use, with manageable side effects, making it a key option for HCC patients.
Area of Science:
- Hepatocellular Carcinoma Research
- Oncology Drug Efficacy
- Clinical Trial Analysis
Background:
- Sorafenib (Nexavar®) is the only approved systemic therapy for hepatocellular carcinoma (HCC).
- Its approval stems from the SHARP and Sorafenib Asia-Pacific trials in Child-Pugh class A patients.
- Real-world studies like GIDEON extend evidence to select Child-Pugh class B patients.
Purpose of the Study:
- To review the efficacy and safety of sorafenib in hepatocellular carcinoma treatment.
- To discuss its role in Child-Pugh class A and B patients.
- To highlight management strategies for sorafenib-related adverse events.
Main Methods:
- Analysis of pivotal clinical trials (SHARP, Sorafenib AP).
- Review of real-world evidence (GIDEON study).
- Evaluation of safety and tolerability data.
Main Results:
- Sorafenib significantly improved overall survival (OS) and time to radiological progression (TTP) versus placebo in advanced HCC (Child-Pugh A).
- No significant difference in time to symptomatic progression (TTSP) was observed.
- Real-world data confirm sorafenib's utility in select Child-Pugh B patients, though with shorter OS.
Conclusions:
- Sorafenib remains a crucial treatment option for advanced hepatocellular carcinoma.
- Its established safety profile and manageable adverse effects, like hand-foot skin reactions, support its continued use.
- Evidence supports sorafenib's application in both Child-Pugh A and carefully selected Child-Pugh B HCC patients.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...